Skip to main content

Aldomet Disease Interactions

There are 8 disease interactions with Aldomet (methyldopa).

Major

Methyldopa (applies to Aldomet) liver disease

Major Potential Hazard, High plausibility.

The use of methyldopa is contraindicated in patients with active liver disease, such as active hepatitis or active cirrhosis, and in patients with previous methyldopa- associated liver disorders. Hepatotoxicity is an uncommon but toxic effect of methyldopa. Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to liver disease.

References

  1. Goldstein GB, Lam KC, Mistillis SP (1973) "Drug-induced active chronic hepatitis." Dig Dis, 18, p. 177-84
  2. Bonkowsky HL, Brisbane J (1976) "Colitis and hepatitis caused by methyldopa." JAMA, 236, p. 1602-3
  3. Miller AC, Reid WM (1976) "Methyldopa-induced granulomatous hepatitis." JAMA, 235, p. 2001-2
  4. Rodman JS, Deutsch DJ, Gutman SI (1976) "Methyldopa hepatitis: a report of six cases and review of the literature." Am J Med, 60, p. 941-8
  5. Cacace LG, Cohen M (1976) "Alpha-methyldopa (aldomet) hepatitis." Drug Intell Clin Pharm, 10, p. 144-52
  6. Sotaniemi EA, Hokkanen OT, Ahokas JT, et al. (1977) "Hepatic injury and drug metabolism in patients with alpha-methyldopa-induced liver damage." Eur J Clin Pharmacol, 12, p. 429-35
  7. Thomas E, Rosenthal WS, Zapiach L, Micci D (1977) "Spectrum of methyldopa liver injury." Am J Gastroenterol, 68, p. 125-33
  8. Puppala AR, Steinheber FU (1977) "Fulminant hepatic failure associated with methyldopa." Am J Gastroenterol, 68, p. 579-81
  9. Bezahler GH (1982) "Case report: fatal methyldopa-associated granulomatous hepatitis and myocarditis." Am J Med Sci, 283, p. 41-5
  10. Neuberger J, Kenna JG, Aria KN, Williams R (1985) "Antibody mediated hepatocyte injury in methyldopa induced hepatotoxicity." Gut, 26, p. 1233-9
  11. Moses A, Zahger D, Amir G (1989) "Cholestatic liver injury after prolonged exposure to methyldopa." Digestion, 42, p. 57-60
  12. Lawson DH, Gloss D, Jick H (1978) "Adverse reactions to methyldopa with particular reference to hypotension." Am Heart J, 96, p. 572-9
  13. (2001) "Product Information. Aldomet (methyldopa)." Merck & Co., Inc
View all 13 references
Moderate

Methyldopa (applies to Aldomet) cerebrovascular disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: History - Cerebrovascular Disease

Rarely, involuntary choreoathetotic movements have been observed during therapy with methyldopa in patients with severe bilateral cerebrovascular disease. If these movements occur, therapy should be stopped.

References

  1. (2001) "Product Information. Aldomet (methyldopa)." Merck & Co., Inc
Moderate

Methyldopa (applies to Aldomet) dialysis

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: hemodialysis

Methyldopa is removed by dialysis. Patients receiving methyldopa and undergoing dialysis may occasionally become hypertensive.

References

  1. Yeh BK, Dayton PG, Waters WC III (1970) "Removal of alpha-methyldopa (aldomet) in man by dialysis (35155)." Proc Soc Exp Biol Med, 135, p. 840-3
  2. Myhre E, Brodwall EK, Stenbaek O, Hansen T (1972) "The renal excretion of methyldopa." Scand J Clin Lab Invest, 29, p. 201-4
  3. Myhre E, Stenbaek O, Rugstad HE, et al. (1982) "Pharmacokinetics of methyldopa in renal failure and bilaterally nephrectomized patients." Scand J Urol Nephrol, 16, p. 257-63
  4. (2001) "Product Information. Aldomet (methyldopa)." Merck & Co., Inc
View all 4 references
Moderate

Methyldopa (applies to Aldomet) hemolytic anemia

Moderate Potential Hazard, Low plausibility. Applicable conditions: Bleeding

Hemolytic anemia has occurred rarely during therapy with methyldopa and may be associated with a (+) direct Coombs. Therapy with methyldopa should be administered cautiously to patients with anemia or a predisposition to hemolytic syndromes. Clinical monitoring of hematopoietic function, including a baseline hematological profile, is recommended. If Coombs- positive hemolytic anemia occurs, the cause may be methyldopa and the drug should be discontinued

References

  1. Distenfeld A, Florita C, Gelfand ML (1970) "Hemolytic anemia induced by alpha-methyldopa." N Y State J Med, Feb, p. 570-3
  2. Nelson RB Jr, Nelson RB III (1977) "Methyldopa-associated intravascular hemolysis." Arch Intern Med, 137, p. 1260-1
  3. Roy A, Ghosh ML (1981) "Coombs positive haemolytic anaemia due to methyldopa." Br J Clin Pract, 35, 54, 58
  4. (2001) "Product Information. Aldomet (methyldopa)." Merck & Co., Inc
View all 4 references
Moderate

Methyldopa (applies to Aldomet) leukopenia

Moderate Potential Hazard, Low plausibility. Applicable conditions: Neutropenia

Rare reports of reversible reduction in white blood cell count, primarily neutrophils, have been noted. White blood cell counts returned to normal with discontinuation of methyldopa. Therapy with methyldopa should be administered cautiously in patients with a history of or predisposition to decreased white blood cell or neutrophil counts. Clinical monitoring of hematopoietic function is recommended.

References

  1. (2001) "Product Information. Aldomet (methyldopa)." Merck & Co., Inc
Moderate

Methyldopa (applies to Aldomet) peripheral edema

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Congestive Heart Failure, Fluid Retention

Methyldopa may cause edema or weight gain associated with sodium retention. Therapy with methyldopa should be administered cautiously in patients adversely affected by sodium and water retention.

References

  1. Varkel Y, Braester A, Nusem D, Shkolnik T (1988) "Methyldopa-induced syndrome of inappropriate antidiuretic hormone-secretion and bone marrow granulomatosis." Drug Intell Clin Pharm, 22, p. 700-1
  2. (2001) "Product Information. Aldomet (methyldopa)." Merck & Co., Inc
Moderate

Methyldopa (applies to Aldomet) pheochromocytoma

Moderate Potential Hazard, Moderate plausibility.

Methyldopa causes fluorescence in urine samples at the same wave lengths as catecholamines, falsely high levels of urinary catecholamines may be reported. This will interfere with the diagnosis of pheochromocytoma. It is important to recognize this phenomenon before a patient with a possible pheochromocytoma is subjected to surgery. Methyldopa is not recommended for the treatment of patients with pheochromocytoma.

References

  1. Cregler LL, Mark H (1987) "Second-degree atrioventricular block and alpha-methyldopa: a probable connection." Mt Sinai J Med, 54, p. 168-70
  2. Rosen B, Ovsyshcher IA, Zimlichman R (1988) "Complete atrioventricular block induced by methyldopa." Pacing Clin Electrophysiol, 11, p. 1555-8
  3. (2001) "Product Information. Aldomet (methyldopa)." Merck & Co., Inc
Minor

Methyldopa (applies to Aldomet) psychoses

Minor Potential Hazard, Low plausibility. Applicable conditions: Psychosis

Rare symptoms of psychoses, such as hallucinations and delirium, and vivid dreams and nightmares have been reported during methyldopa therapy. Therapy with methyldopa should be administered cautiously to patients with a history of or predisposition to these conditions.

References

  1. Endo M, Hirai KO, Ohara M (1978) "Paranoid-hallucinatory state induced in a depressive patient by methyldopa: a case report." Psychoneuroendocrinology, 3, p. 211-5
  2. Wurzelmann J, Frishman WH, Aronson M, et al. (1987) "Neuropsychological effects of antihypertensive drugs." Cardiol Clin, 5, p. 689-701
  3. Labbate LA, Holzgang AJ (1989) "Manic syndrome after discontinuation of methyldopa." Am J Psychiatry, 146, p. 1075-6
  4. Tchen P, Luchins DJ, Rose RP (1990) "Possibility of depression as a side effect of methyldopa." Am J Psychiatry, 147, p. 128
  5. (2001) "Product Information. Aldomet (methyldopa)." Merck & Co., Inc
View all 5 references

Aldomet drug interactions

There are 303 drug interactions with Aldomet (methyldopa).

Aldomet alcohol/food interactions

There are 2 alcohol/food interactions with Aldomet (methyldopa).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer